leading brands of glp-1 agonists in biopharma Latin America Glucagon-like Peptide-1 Market - Evolution of GLP‐1 Receptor Agonists

95% CI 0.791.39) or 4-point MACE (HR 0.95

STEP series clinical trials of Semaglutide Novo's two obesity products, Wegovy and Saxenda, have generated DKK 16.86bn (USD 2.5bn) in sales throughout 2022, doubling the preceding year's result of DKK 8.4bn (USD 1.2bn) an increase of 101%

doi: 10.1016/S2213-8587(24)00272-9

Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy

518,519,520,521 Hepatocellular carcinoma (HCC) Initially developed for treating diabetes, GLP-1RAs have shown potential in treating NASH, which is closely related to HCC

GIP stimulates also glucose-dependent insulin release in people without diabetes and may have a role in appetite regulation: despite mixed findings, preclinical research suggests that the addition of GIP RA may enhance appetite suppression and WL associated with a fixed-dose of GLP-1 RA (Fig